Table 3 Correlations between clinicopathological features, USP22, SIRT1 and E-cadherin expression in PTC patients (N = 40)
| Â | USP 22 | p | SIRT1 | p | E-cadherin | p | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low | High | Low | High | Low | High | ||||||||||
N = 15 | N = 25 | N = 21 | N = 19 | N = 25 | N = 15 | ||||||||||
Age.Group | |||||||||||||||
 < 40y | 6 | 40.0% | 14 | 56.0% | 0.327 | 7 | 33.3% | 13 | 68.4% | 0.027 | 15 | 60.0% | 5 | 33.3% | 0.102 |
 = > 40y | 9 | 60.0% | 11 | 44.0% |  | 14 | 66.7% | 6 | 31.6% |  | 10 | 40.0% | 10 | 66.7% |  |
Sex | |||||||||||||||
 M | 5 | 33.3% | 6 | 24.0% | 0.522 | 6 | 28.6% | 5 | 26.3% | 0.873 | 7 | 28.0% | 4 | 26.7% | 0.927 |
 F | 10 | 66.7% | 19 | 76.0% |  | 15 | 71.4% | 14 | 73.7% |  | 18 | 72.0% | 11 | 73.3% |  |
Histo-pathological subtype | |||||||||||||||
 PTC conv | 14 | 93.3% | 22 | 88.0% | 0.586 | 20 | 95.2% | 16 | 84.2% | 0.246 | 22 | 88.0% | 14 | 93.3% | 0.586 |
 PTC FV | 1 | 6.7% | 3 | 12.0% |  | 1 | 4.8% | 3 | 15.8% |  | 3 | 12.0% | 1 | 6.7% |  |
Stage | |||||||||||||||
 I | 6 | 40.0% | 1 | 4.0% | < 0.001 | 7 | 33.3% | 0 | 0.0% | < 0.001 | 3 | 12.0% | 4 | 26.7% | 0.044 |
 II | 7 | 46.7% | 4 | 16.0% |  | 9 | 42.9% | 2 | 10.5% |  | 4 | 16.0% | 7 | 46.7% |  |
 III | 1 | 6.7% | 13 | 52.0% |  | 2 | 9.5% | 12 | 63.2% |  | 12 | 48.0% | 2 | 13.3% |  |
 IV | 1 | 6.7% | 7 | 28.0% |  | 3 | 14.3% | 5 | 26.3% |  | 6 | 24.0% | 2 | 13.3% |  |
Tumor size | |||||||||||||||
 <4 cm | 13 | 86.7% | 12 | 48.0% | 0.014 | 17 | 81.0% | 8 | 42.1% | 0.011 | 12 | 48.0% | 13 | 86.7% | 0.014 |
 = > 4 cm | 2 | 13.3% | 13 | 52.0% |  | 4 | 19.0% | 11 | 57.9% |  | 13 | 52.0% | 2 | 13.3% |  |
Surgery (thyroidectomy) | |||||||||||||||
 Total | 6 | 40.0% | 14 | 56.0% | 0.203 | 10 | 47.6% | 10 | 52.6% | 0.121 | 14 | 56.0% | 6 | 40.0% | 0.094 |
 Subtotal | 5 | 33.3% | 2 | 8.0% |  | 6 | 28.6% | 1 | 5.3% |  | 2 | 8.0% | 5 | 33.3% |  |
 Total + BND | 4 | 26.7% | 8 | 32.0% |  | 4 | 19.0% | 8 | 42.1% |  | 9 | 36.0% | 3 | 20.0% |  |
 Lobectomy | 0 | 0.0% | 1 | 4.0% |  | 1 | 4.8% | 0 | 0.0% |  | 0 | 0.0% | 1 | 6.7% |  |
Multifocality | 2 | 13.3% | 15 | 60.0% | 0.004 | 4 | 19.0% | 13 | 68.4% | 0.002 | 14 | 56.0% | 3 | 20.0% | 0.026 |
LN involvement | 4 | 26.7% | 20 | 80.0% | 0.001 | 6 | 28.6% | 18 | 94.7% | < 0.001 | 19 | 76.0% | 5 | 33.3% | 0.008 |
Vascular invasion | 1 | 6.7% | 9 | 36.0% | 0.038 | 3 | 14.3% | 7 | 36.8% | 0.015 | 8 | 32.0% | 2 | 13.3% | 0.007 |
Capsular invasion | 1 | 6.7% | 14 | 56.0% | 0.002 | 4 | 19.0% | 11 | 57.9% | 0.011 | 12 | 48.0% | 3 | 20.0% | 0.047 |
Extrathyroid extension | 1 | 6.7% | 12 | 48.0% | 0.007 | 3 | 14.3% | 10 | 52.6% | 0.01 | 11 | 44.0% | 2 | 13.3% | 0.045 |
Distant metastasis | 1 | 6.7% | 7 | 28.0% | 0.032 | 3 | 14.3% | 5 | 26.3% | 0.042 | 6 | 24.0% | 2 | 13.3% | 0.014 |
Lung Mets | 1 | 6.7% | 3 | 12.0% | 0.559 | 2 | 9.5% | 2 | 10.5% | 0.871 | 3 | 12.0% | 1 | 6.7% | 0.559 |
Bone Mets | 1 | 6.7% | 1 | 4.0% | 0.731 | 1 | 4.8% | 1 | 5.3% | 0.911 | 2 | 8.0% | 0 | 0.0% | 0.251 |
Brain Mets | 0 | 0.0% | 1 | 4.0% | 0.423 | 0 | 0.0% | 1 | 5.3% | 0.274 | 1 | 4.0% | 0 | 0.0% | 0.423 |
Mediastinal Mets | 1 | 6.7% | 0 | 0.0% | 0.2 | 0 | 0.0% | 1 | 5.3% | 0.274 | 1 | 4.0% | 0 | 0.0% | 0.423 |